China-based HitGen Inc. (SHA: 688222) has announced strategic partnerships with LabCentral, a prominent life science and biotechnology startup incubation platform; BioLabs, an international network of membership-based shared laboratory and office spaces; and MBC BioLabs, a provider of shared laboratory facilities.
Recognized as a leader in DNA-encoded library (DEL) technology and its applications for early-stage small molecule drug discovery, HitGen will offer its extensive DEL portfolio, which includes billions of novel, drug-like small molecules, to innovative firms leveraging the MBC BioLabs platform. This significant collaboration allows biotechnology startups to swiftly screen and develop novel drug candidates across various therapeutic areas, utilizing HitGen’s expansive DEL library. The partnerships with MBC BioLabs, BioLabs, and LabCentral are set to enhance service offerings, providing cutting-edge technology and resources designed to accelerate research and development processes for associated enterprises.- Flcube.com
